Effect of Sitopaladi Churna in the treatment of Kasa (Stable chronic Bronchitis)

Not Applicable

Completed

• Conditions: Health Condition 1: null- Patients suffering from Chronic Stable Bronchitis and Patients having FEV1 80%.

• Registration Number: CTRI/2017/10/010253
• Lead Sponsor: Central Council For Research in Ayurvedic Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-07-26
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 67

Inclusion Criteria

1.Patients of either sex aged between 18 to 65years.

2.Patients suffering from Chronic Stable Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row).

3.Patients having FEV1 > 80%.

4.Patient willing and able to participate in the study for 16 weeks.

Exclusion Criteria

1.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc.

2.Known case of Diabetes Mellitus

3.Patients with poorly controlled Hypertension ( >=160 / 100 mmHg).

4.Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.

5.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc).

6.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.

7.Symptomatic patients with clinical evidence of Heart failure.

8.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL).

9.Smokers/alcoholics and/or drug abusers.

10.Patients who have completed participation in any other clinical trial during the past six (06) months.

11.Any other condition which the Investigator thinks may jeopardize the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified